CYTOSCAN(R) DX

System, Microarray-based, Genome-wide, Postnatal Chromosomal Abnormality Detection

Affymetrix, Inc.

The following data is part of a De Novo classification by Affymetrix, Inc. with the FDA for Cytoscan(r) Dx.

Pre-market Notification Details

DeNovo IDDEN130018
Device Name:CYTOSCAN(R) DX
ClassificationSystem, Microarray-based, Genome-wide, Postnatal Chromosomal Abnormality Detection
Applicant Affymetrix, Inc. 3420 Central Expressway Santa Clara,  CA  95051
ContactEric Fung
Product CodePFX  
CFR Regulation Number866.5920 [🔎]
DecisionGranted (DENG)
510(k) Premarket NotificationK130313
Review Advisory BoardPathology
Classification AdvisoryImmunology
TypePost-NSE
Date Received2013-12-18
Decision Date2014-01-17
FDA ReviewDecision Summary
Reclassification Order:Reclassification Order

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.